journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions

journal
https://read.qxmd.com/read/30778875/the-efficacy-and-safety-of-aerosolized-iloprost-in-pulmonary-arterial-hypertension-a-systematic-review-and-meta-analysis
#1
Hongyu Kuang, Qiang Li, Qijian Yi, Tiewei Lu
BACKGROUND: This systematic review and meta-analysis was conducted to investigate the efficacy and safety of the chronic administration of aerosolized iloprost for pulmonary arterial hypertension (PAH). METHODS: All the relevant studies were obtained from three databases, namely, PubMed, Web of Science and the Cochrane Library, from the inception of each database to June 1, 2018. In our study, chronic treatment was defined as a period lasting at least 3 months...
February 19, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30767126/cardiovascular-protection-with-anti-hyperglycemic-agents
#2
REVIEW
Prakash Deedwania, Tushar Acharya
Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c ) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no effect on reducing macrovascular events like heart attack, stroke, and heart failure. It has been postulated that hypoglycemia may counterbalance some of the beneficial effects of anti-hyperglycemic agents, but this is not proven...
February 15, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30746615/efficacy-and-safety-of-ticagrelor-compared-with-clopidogrel-in-patients-with-end-stage-renal-disease-with-acute-myocardial-infarction
#3
Chien-Ho Lee, Tzu-Hsien Tsai, Cheng-Jui Lin, Shu-Kai Hsueh, Wen-Jung Chung, Cheng-I Cheng
OBJECTIVE: This study investigated the efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease (ESRD) and acute myocardial infarction (AMI). METHODS: We retrospectively enrolled patients who had received regular dialysis and had undergone percutaneous coronary intervention (PCI) for AMI at our hospital between January 2013 and December 2016. Outcomes analyzed included cardiovascular death, death from any cause, MI, stroke, and bleeding events...
February 12, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30739300/correction-to-plasma-vitamin-k-1-levels-in-italian-patients-receiving-oral-anticoagulant-therapy-for-mechanical-heart-prosthesis-a-case-control-study
#4
Arturo Cafolla, Alessandra Gentili, Clodomiro Cafolla, Virginia Perez, Erminia Baldacci, Daniela Pasqualetti, Bruna Demasi, Roberta Curini
Throughout the manuscript the units of plasma vitamin K1 concentration which previously read.
February 9, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30737754/efficacy-and-safety-of-dual-blockade-of-the-renin-angiotensin-aldosterone-system-in-diabetic-kidney-disease-a-meta-analysis
#5
REVIEW
Yanhuan Feng, Rongshuang Huang, Janet Kavanagh, Lingzhi Li, Xiaoxi Zeng, Yi Li, Ping Fu
INTRODUCTION: Current guidelines recommend renin-angiotensin-aldosterone system (RAAS) inhibitors in the treatment of diabetic kidney disease (DKD). However, evidence suggests that the combined use of RAAS blockers may be associated with increased rates of adverse events. OBJECTIVES: Our objective was to examine the efficacy and safety of dual blockade of the RAAS in patients with DKD. METHODS: This was a systematic review and meta-analysis of randomized controlled trials (RCTs) published between January 1990 and January 2018 sourced via the PubMed, EMBASE, and Cochrane Library databases...
February 9, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30714088/drug-treatment-of-hyperlipidemia-in-chinese-patients-focus-on-the-use-of-simvastatin-and-ezetimibe-alone-and-in-combination
#6
REVIEW
Sheng-Na Han, Wei-Hong Yang, Jian-Jian Yin, Hai-Long Tao, Li-Rong Zhang
Elevated serum low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD). Many guidelines recommend LDL-C as a primary treatment target, and statins represent the cornerstone of treatment for lipid management. Recently revised guidelines recommend even more intense management of LDL-C, especially in patients at moderate and high risk. However, LDL-C levels in the Chinese population differ from those in Western populations, and the benefits and safety of the maximum allowable dose of statins have yet to be determined...
February 4, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30714087/potential-protective-role-of-blood-pressure-lowering-drugs-on-the-balance-between-hemostasis-and-fibrinolysis-in-hypertensive-patients-at-rest-and-during-exercise
#7
REVIEW
Annabella Braschi
In patients with hypertension, the triad represented by endothelial dysfunction, platelet hyperactivity, and altered fibrinolytic function disturbs the equilibrium between hemostasis and fibrinolysis and translates into a hypercoagulable state, which underlies the risk of thrombotic complications. This article reviews the scientific evidence regarding some biological effects of antihypertensive drugs, which can protect patients from the adverse consequences of hypertensive disease, improving endothelial function, enhancing antioxidant activity, and restoring equilibrium between hemostatic and fibrinolytic factors...
February 4, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30693439/how-might-bromodomain-and-extra-terminal-bet-inhibitors-operate-in-cardiovascular-disease
#8
C Mary Schooling, Jie V Zhao
Bromodomain and extra-terminal (BET) inhibitors, acting via epigenetic mechanisms, have been developed recently as potential new treatments for cancer, including prostate cancer, and inflammatory conditions. Some BET inhibitors, such as RVX-208, also raise high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-1 levels. A recent meta-analysis of three small trials (n = 798) found that RVX-208 protected against major adverse cardiovascular events (MACE), raising the question as to whether this protective effect was an artefact, a chance finding, or mediated by HDL-C, anti-inflammatory pathways, or other factors...
January 29, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30680652/rivaroxaban-with-or-without-aspirin-for-the-secondary-prevention-of-cardiovascular-disease-clinical-implications-of-the-compass-trial
#9
REVIEW
Stephen J Nicholls, Adam J Nelson
The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5 mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5 mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin...
January 25, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30671881/improving-survival-in-patients-with-pulmonary-arterial-hypertension-focus-on-intravenous-epoprostenol
#10
Eftychia Demerouti, Panagiotis Karyofyllis, Athanassios Manginas, Anastasia Anthi, George Karatasakis, George Athanassopoulos, Vassilios Voudris
Pulmonary arterial hypertension represents a devastating disease, causing progressive increase of pulmonary vascular resistance leading to right ventricular dysfunction and death. Therapeutic management has rapidly advanced in recent years due to improved understanding of pathophysiology and new drugs have been developed; however, survival remains poor. Oral agents as phosphodiesterase type V inhibitors, the soluble guanylyl cyclase stimulator riociguat, the prostacyclin receptor agonist selexipag and the endothelin receptor antagonists have each achieved evidence-based validation and are recommended for pulmonary arterial hypertension...
January 23, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30637626/clinical-pharmacokinetics-safety-and-tolerability-of-a-novel-first-in-class-trpv4-ion-channel-inhibitor-gsk2798745-in-healthy-and-heart-failure-subjects
#11
Navin Goyal, Pete Skrdla, Rosemary Schroyer, Subramanya Kumar, Disala Fernando, Anna Oughton, Nicola Norton, Dennis L Sprecher, Joseph Cheriyan
INTRODUCTION AND OBJECTIVE: Pulmonary capillary endothelial transient receptor potential vanilloid 4 (TRPV4) channel plays a critical role in mediating the development of cardiogenic pulmonary edema. GSK2798745 is a first-in-class, highly potent, selective, orally active TRPV4 channel blocker being evaluated in a first-time-in-humans study (NCT02119260). METHODS: GSK2798745 was administered in a randomized, placebo-controlled study design to healthy volunteers in three separate cohorts as single escalating doses, with and without food, and as once-daily repeat doses for up to 14 days, respectively...
January 14, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30610681/do-cholesteryl-ester-transfer-protein-inhibitors-have-a-role-in-the-treatment-of-cardiovascular-disease
#12
Stephen J Nicholls, Adam J Nelson
Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism and has presented an attractive target for drug development, primarily resting on the hope that CETP inhibition would reduce cardiovascular events through its ability to increase levels of high-density lipoprotein cholesterol (HDL-C). However, clinical development of CETP inhibitors has proven disappointing, with a spectrum of results spanning from evidence of harm, to futility, to only modest benefit in large-scale cardiovascular outcomes trials...
January 5, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30565156/tackling-residual-atherosclerotic-risk-in-statin-treated-adults-focus-on-emerging-drugs
#13
REVIEW
Kohei Takata, Stephen J Nicholls
Epidemiological studies and meta-analyses have consistently suggested the importance of lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular (CV) events. However, these studies and mechanistic studies using intracoronary imaging modalities have reported patients who continue to experience CV events or disease progression despite optimal LDL-C levels on statins. These findings, including statin intolerance, have highlighted the importance of exploring additional potential therapeutic targets to reduce CV risk...
December 19, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30565155/low-dose-aspirin-for-primary-prevention-of-cardiovascular-events-in-elderly-japanese-patients-with-atherosclerotic-risk-factors-subanalysis-of-a-randomized-clinical-trial-jppp-70
#14
Masahiro Sugawara, Yoshio Goto, Tsutomu Yamazaki, Tamio Teramoto, Shinichi Oikawa, Kazuyuki Shimada, Shinichiro Uchiyama, Katsuyuki Ando, Naoki Ishizuka, Mitsuru Murata, Kenji Yokoyama, Yukari Uemura, Yasuo Ikeda
INTRODUCTION: This post hoc subanalysis of the randomized Japanese Primary Prevention Project investigated whether once-daily low-dose aspirin versus no aspirin reduced the risk of cardiovascular events (CVEs) in patients aged ≥ 70 years with atherosclerotic risk factors. METHODS: Patients aged < 70 years (young-old) or ≥ 70 years (old) with hypertension, dyslipidemia, or diabetes participated between 2005 and 2007. Patients were randomized 1:1 to receive 100 mg enteric-coated aspirin once daily or no aspirin plus standard of care...
December 18, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30471054/trends-in-hospital-visits-for-generic-and-brand-name-warfarin-users-in-qu%C3%A3-bec-canada-a-population-based-time-series-analysis
#15
Jacinthe Leclerc, Claudia Blais, Louis Rochette, Denis Hamel, Line Guénette, Paul Poirier
BACKGROUND: Federal standards authorize the commercialization of generic medicines after bioequivalence versus the brand-name originator has been demonstrated. For drugs with narrow therapeutic indexes, such as warfarin, the accepted difference in bioavailability is ≤ 10%. No systematic pharmacovigilance studies are conducted once generics become available. OBJECTIVE: We aimed to assess the impact of the arrival of generic warfarin on hospital visit trends (hospital admissions or emergency room consultations) in warfarin users...
November 24, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30182350/efficacy-and-safety-of-the-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-ischemic-heart-disease-a-meta-analysis-of-phase-iii-randomized-trials
#16
REVIEW
Linghua Fu, Wengen Zhu, Lin Huang, Jinzhu Hu, Jianyong Ma, Gregory Y H Lip, Kui Hong
BACKGROUND: There are conflicting published data on non-vitamin K antagonist oral anticoagulants (NOACs), with varying evidence of benefit or harm in acute coronary syndrome (ACS) and non-ACS cohorts. To explore the efficacy and safety of NOAC use in patients with ischemic heart disease (IHD), we conducted a meta-analysis of phase III randomized controlled trials (RCTs). METHODS: We systematically searched the Cochrane Library, PubMed, and Embase databases. A random-effect model was selected to pool the effect measurement estimates (hazard ratios [HRs] and 95% confidence intervals [CIs])...
February 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30132141/early-and-late-stent-thrombosis-in-patients-with-versus-without-diabetes-mellitus-following-percutaneous-coronary-intervention-with-drug-eluting-stents-a-systematic-review-and-meta-analysis
#17
Jun Yuan, Guang Ma Xu
BACKGROUND: Nowadays, drug-eluting stents (DES) are most commonly used compared with bare metal stents (BMS) since the former are associated with significantly lower rates of revascularization following percutaneous coronary intervention (PCI). However, unpredictable in-stent thrombosis is a major concern with DES, especially in patients with diabetes mellitus. OBJECTIVE: In this analysis, we aimed to systematically compare early and late stent thrombosis in patients with versus without diabetes mellitus following PCI with DES...
December 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30066080/clinical-use-of-digitalis-a-state-of-the-art-review
#18
REVIEW
Thomas F Whayne
The history of digitalis is rich and interesting, with the first use usually attributed to William Withering and his study on the foxglove published in 1785. However, some knowledge of plants with digitalis-like effects used for congestive heart failure (CHF) was in evidence as early as Roman times. The active components of the foxglove (Digitalis purpurea and Digitalis lanata) are classified as cardiac glycosides or cardiotonic steroids and include the well-known digitalis leaf, digitoxin, and digoxin; ouabain is a rapid-acting glycoside usually obtained from Strophanthus gratus...
December 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/29987548/oral-antiplatelet-therapy-for-secondary-prevention-of-acute-coronary-syndrome
#19
REVIEW
Jeffrey S Berger
Patients surviving an acute coronary syndrome (ACS) remain at increased risk of ischemic events long term. This paper reviews current evidence and guidelines for oral antiplatelet therapy for secondary prevention following ACS, with respect to decreased risk of ischemic events versus bleeding risk according to individual patient characteristics and risk factors. Specifically, data are reviewed from clinical studies of clopidogrel, prasugrel, ticagrelor and vorapaxar, as well as the results of systematic reviews and meta-analyses looking at the benefits and risks of oral antiplatelet therapy, and the relative merits of shorter versus longer duration of dual antiplatelet therapy, in different patient groups...
December 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/29915905/antithromboembolic-strategies-for-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention
#20
REVIEW
Ayesha Ather, Benjamin Laliberte, Brent N Reed, Ashley Schenk, Kristin Watson, Sandeep Devabhakthuni, Vincent Y See
We set out to synthesize available data on antithrombotic strategies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), with a focus on triple antithrombotic therapy (triple therapy [TT]; dual antiplatelet therapy plus an anticoagulant) versus dual therapy (DT; one antiplatelet agent and an anticoagulant). We searched OVID MEDLINE and PubMed from January 2005 to September 2017 using the search terms oral anticoagulant, triple therapy, dual therapy, acute coronary syndrome, percutaneous coronary intervention, and atrial fibrillation (limited to randomized controlled trials, observational studies, English language, minimum 6-12 months of follow-up, minimum 100 human patients)...
December 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
journal
journal
35888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"